@article {GRISWOLD2016366,
	title = {Large scale accelerator production of 225Ac: Effective cross sections for 78{\textendash}192MeV protons incident on 232Th targets},
	journal = {Applied Radiation and Isotopes},
	volume = {118},
	year = {2016},
	pages = {366 - 374},
	abstract = {Actinium-225 and 213Bi have been used successfully in targeted alpha therapy (TAT) in preclinical and clinical research. This paper is a continuation of research activities aiming to expand the availability of 225Ac. The high-energy proton spallation reaction on natural thorium metal targets has been utilized to produce millicurie quantities of 225Ac. The results of sixteen irradiation experiments of thorium metal at beam energies between 78 and 192MeV are summarized in this work. Irradiations have been conducted at Brookhaven National Laboratory (BNL) and Los Alamos National Laboratory (LANL), while target dissolution and processing was carried out at Oak Ridge National Laboratory (ORNL). Excitation functions for actinium and thorium isotopes, as well as for some of the fission products, are presented. The cross sections for production of 225Ac range from 3.6 to 16.7mb in the incident proton energy range of 78{\textendash}192MeV. Based on these data, production of curie quantities of 225Ac is possible by irradiating a 5.0gcm-2 232Th target for 10 days in either BNL or LANL proton irradiation facilities.},
	keywords = {Ac, actinium, Alpha-emitting, Ba, Ce, MO, Proton irradiation, RADIOTHERAPY, Th, Thorium},
	issn = {0969-8043},
	doi = {https://doi.org/10.1016/j.apradiso.2016.09.026},
	url = {http://www.sciencedirect.com/science/article/pii/S0969804316307795},
	author = {J.R. Griswold and D.G. Medvedev and J.W. Engle and R. Copping and J.M. Fitzsimmons and V. Radchenko and J.C. Cooley and M.E. Fassbender and D.L. Denton and K.E. Murphy and A.C. Owens and E.R. Birnbaum and K.D. John and F.M. Nortier and D.W. Stracener and L.H. Heilbronn and L.F. Mausner and S. Mirzadeh}
}
@article {1052,
	title = {Radiohalogens for imaging and therapy},
	journal = {Chemical Society Reviews},
	volume = {34},
	number = {2},
	year = {2005},
	note = {ISI Document Delivery No.: 890PETimes Cited: 34Cited Reference Count: 41},
	pages = {153-163},
	type = {Review},
	abstract = {Radiohalogens play a very important role in radiopharmaceuticals used for medical imaging ( now referred to as molecular imaging) and therapy applications. Development of new radiopharmaceuticals that have radiohalogens incorporated requires an understanding of parameters that are unique to chemistry involving these radionuclides. Those parameters include requirement for production and purification of the halogen radionuclides, as well as development of reaction conditions for use with high specific activity short-lived radionuclides. In this tutorial review, several radiohalogens, their radiolabeling chemistry and their application to medical imaging and therapy are discussed.},
	keywords = {BRAIN, CANCER, F-18, LIGAND, MONOCLONAL-ANTIBODIES, PET, POSITRON-EMISSION-TOMOGRAPHY, RADIOIODINATION, RADIOTHERAPY, SPECT},
	isbn = {0306-0012},
	url = {<Go to ISI>://000226522500005},
	author = {Adam,Michael J. and Wilbur, D. S.}
}
